Hong Kong-based biotechnology company Arbele announced on Wednesday that it has partnered with BioAI, a US provider of multimodal AI in precision medicine, and China-based global contract manufacturing organisation Chime Biologics.

The collaboration with BioAI Health is aimed at developing a prototype of an immunohistochemistry (IHC)-based quantification algorithm. It will use the PredictX platform to develop AI-based models using Arbele's clinical trial data on colorectal cancer (CRC) biomarker screening.

The partnership with Chime Biologics is aimed at accelerating chemistry, manufacturing and control (CMC) process development of the novel designs of antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs). It supports multiple pipelines of approximately 10 first-in-class and best-in-class immunotherapeutics, including monoclonal, bispecific/biparatopic and TriAx antibodies, in the next three years. The aim is to ensure that Arbele will continue to have at least one or two new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next five years without any technical and supply-chain interruptions. The first product to be produced will be anti-CDH17 ADC (ARB102A), for IND submission in early 2025.